499.75
+11.86%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aarti Drugs
Its shares trade on NSE under the ticker AARTIDRUGS.NS. It has been listed since 12 May 1993. In the fiscal year to 31 March 2026, it reported revenue of ₹25.65bn and net income of ₹1.95bn. At that date it held total assets of ₹28.15bn and shareholders' equity of ₹15.49bn.
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm operates through pharmaceuticals segment. The firm's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The firm's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 May 1993
- Employees
- 1,500
- Website
- aartidrugs.co.in ↗
Leadership
Pay as last reported
- Shri. Prakash PatilChairman of the Board, Chief Executive Officer, Managing Director, Executive Director, since 1985₹29.4m
- Shri. Chandrakant GogriChairman Emeritus₹90,000
- Shri. Adhish PatilChief Financial Officer, Chief Operating Officer₹10.0m
- Mr. Rushikesh DeoleCompliance Officer, Company Secretary₹1.5m
- Shri. Harshit SavlaJoint Managing Director, Executive Director, since 1987₹26.9m
- Shri. Rashesh GogriManaging Director, Executive Director, since 2012₹26.9m
- Shri. Uday PatilExecutive Director₹3.7m
- Shri. Harit Pragji ShahExecutive Director₹26.9m
- Shri. Narendra SalviNon-Executive Director₹160,000
- Shri. Hasmukh DedhiaNon-Executive Independent Director₹265,000
- Ms. Neha GadaNon-Executive Independent Director₹275,000
- Shri. Sandeep JoshiNon-Executive Independent Director₹185,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 42
- Social
- 47
- Governance
- 18
- Direct emissions (scope 1)
- 54,834 t
- Energy emissions (scope 2)
- 80,250 t
- Women in the workforce
- 11.12994%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aarti Drugs Ltd. develops and markets pharmaceutical products including ciprofloxacin hydrochloride and metronidazole.
- The company employs 1,500 full-time employees in Mumbai, Maharashtra.
- Aarti Drugs Ltd. operates through the pharmaceuticals segment with API and specialty chemical products.
Weaknesses
- The company's products under development include itraconazole and fluconazole.
- Aarti Speciality Chemicals Limited is a subsidiary operating in the pharmaceuticals segment.
- Pinnacle Chile SPA is a subsidiary with limited market presence.
Opportunities
- The firm's pharma intermediates products include celecoxib and clopidogrel for expanding markets.
- Aarti Drugs Ltd. has subsidiaries like Pinnacle Life Science Private Limited for growth.
- The company's API products such as metformin HCL are in high demand.
Threats
- The firm's specialty chemicals products include benzene sulphonyl chloride which faces regulatory scrutiny.
- Aarti Drugs Ltd. operates in the Health Care sector with increasing competition.
- Pinnacle Chile SPA's limited market presence poses a risk to global expansion.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.